Katherine Denby

Cooley advised Cara Therapeutics, Inc. on its $40 million royalty interest purchase and sale agreement with HealthCare Royalty Partners. Michael Tollini and Addison Pierce led the Cooley team advising Cara, which included Bin Wang, Xueqing Li and Jordan Verrilli. Cara, which trades on The NASDAQ Global Market as “CARA,” is a clinical-stage biotech company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors.

Cooley advised Tourmaline Bio, a late-stage clinical biotechnology company, on its merger agreement with Talaris Therapeutics, including a concurrent private placement.

Cooley advised Apollo Endosurgery, a medical device company, on its agreement to be acquired by Boston Scientific in an all-cash transaction with an enterprise value of approximately $615 million.

Cooley advised Zoetis on its $1.35 billion aggregate principal amount of investment-grade unsecured senior notes, $600 million of 5.400% senior notes due 2025, and $750 million of 5.600% senior notes due 2032. Zoetis is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. Eric Blanchard and Madison Jones led the Cooley team.

Cooley advised Allbirds, a global lifestyle brand, on its $348.3 million initial public offering of 23,221,152 shares of Class A common stock, which now trade on the Nasdaq Global Select Market under the symbol BIRD. Partners Nicole Brookshire, Peter Werner and Calise Cheng led the Cooley team advising Allbirds.